12:16:45 EDT Fri 19 Apr 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Helix BioPharma Corp
Symbol C : HBP
Shares Issued 107,236,579
Close 2019-04-15 C$ 0.50
Recent Sedar Documents

Helix BioPharma shareholders approve rollback at AGM

2019-04-16 02:00 ET - News Release

Mr. Slawomir Majewski reports

HELIX BIOPHARMA CORP. REPORTS VOTING RESULTS

Helix BioPharma Corp. has released the voting results of the company's annual and special meeting of shareholders, held on April 15, 2019. In accordance with Section 11.3 of National Instrument 51-102 (Continuous Disclosure Obligations), this news release contains a summary of the results of matters voted on at the meeting.

There were 24 shareholders represented in person or by proxy at the meeting, holding 64,835,119 shares, representing approximately 61.14 per cent of Helix's total issued and outstanding shares.

1. Election of directors

Each of the nominees for election as directors listed in Helix's management information circular dated March 14, 2019, was elected as a director of Helix for the ensuing year or until successors are elected or appointed. Management received proxies in respect of the election of directors of Helix.

       VOTING RESULTS FOR ELECTION OF DIRECTORS

                         Votes for      Votes withheld

                        Number       %   Number      %   

Sylwester Cacek     64,809,116   99.97   16,687   0.03  
Heman Chao          64,808,316   99.97   17,487   0.03  
Artur Gabor         64,809,116   99.97   16,687   0.03  
Slawomir Majewski   64,809,116   99.97   16,687   0.03  

2. Appointment of auditor

BDO Canada LLP, chartered professional accountant, was appointed auditor of Helix until the next annual meeting of shareholders at a remuneration to be fixed by the directors. Management received proxies in respect of the appointment of the auditor of Helix.

        VOTING RESULTS FOR 
      APPOINTMENT OF AUDITOR

      Votes for       Votes withheld

Number            %   Number       %    

64,834,909   100.00       10    0.00   

3. Share consolidation

The special resolution authorizing an amendment to the articles of Helix to consolidate the issued and outstanding common shares of Helix at a ratio of one postconsolidation common share for between five and 25 preconsolidation common shares, as and when determined by the board of directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the special resolution present or represented by proxy at the meeting. Management received proxies in respect of the amendment to the articles of Helix.

       VOTING RESULTS FOR 
       SHARE CONSOLIDATION

     Votes for        Votes against

Number           %    Number      %   

64,804,632   99.95    30,287   0.05 

4. Warrant extension

The resolution authorizing the extension of the expiry date of certain insider warrants by a period of two years was approved by a majority of the votes cast by disinterested shareholders who voted in respect of the resolution present or represented by proxy at the meeting (excluding the votes attaching to 4,499,381 common shares beneficially owned by, directly or indirectly, or under the control or direction of interested insiders). Management received proxies in respect of the extension of the insider warrants of Helix.

        VOTING RESULTS FOR 
         WARRANT EXTENSION

     Votes for        Votes against

Number           %    Number      %   

60,309,735   99.97    16,687   0.03 

About Helix BioPharma Corp.

Helix BioPharma is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and chimeric-antigen-receptor-(CAR)-based cell therapies.

© 2019 Canjex Publishing Ltd. All rights reserved.